Oxidized low density lipoprotein (oxLDL) is believed to play a critical role in the development and progression of atherosclerosis. Accumulation of oxLDL in macrophages and smooth muscle cells causes foam cell formation, an initial step in the disease. Autoantibodies against oxidatively modified LDL can be used as a parameter that consistently mirrors the occurrence of oxidation processes taking place in vivo. In fact, elevated levels of autoantibodies against oxLDL have been detected in the blood stream of patients with coronary artery disease. Moreover, recent studies indicate a correlation between autoantibodies against oxLDL and the progression of carotid atherosclerosis. Increased serum concentrations of oLAB have also been described in various diseases such as pre-eclampsia and systemic lupus erythematosus. Decreased oLAB titers were observed during septicemia and myocardial infarction.
产品描述
Method
Indirect ELISA, HRP/TMB, 12×8-well detachable strips
Sample type
Serum
Sample volume
50 µl / well
Assay time
1.5 h / 30 min / 15 min
Sensitivity
48 mU/ml
Standard range
0 – 1,200 mU/ml
Specificity
Anti-oxidized LDL autoantibodies
Precision
In-between-run (n=5): ≤ 8 % CV
Within-run (n=8): ≤ 4 % CV
